|
Introduction
The manufacturing platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. We have four clinical trials are going by now including GXHPC1, GXNPC1, GXCPC1 and GXIPC1, which the indications are liver cirrhosis, stroke, osteoarthritis and diabetes, respectively.
More Information
|